Stock Price, News, Quote and Profile of GINKGO BIOWORKS HOLDINGS INC(NYSE:DNA) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (5/2/2024, 8:53:09 AM)

0.8496

+0.01 (+0.89%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorMaterials

GICS IndustryChemicals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap1.73B

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 1,292 full-time employees. The company went IPO on 2021-04-19. Its cell programs are designed to enable biological production of products as diverse as therapeutics, key food ingredients and chemicals derived from petroleum. Its Foundry segment consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two assets: the Foundry, biology lab facilities, enabled by investment in workflows, custom software, robotic automation, and data science and analytics. Its Biosecurity segment consists of COVID-19 testing products and services primarily provided to public health authorities. The company also owns the adeno-associated virus capsid discovery and engineering platform assets.